NasdaqGS:IBRXBiotechs
ImmunityBio (IBRX) Tests Its Valuation After UAE ANKTIVA Approval Expands Its Reach
ImmunityBio (IBRX) stock is in focus after the company secured marketing authorization in the United Arab Emirates for ANKTIVA in both BCG unresponsive non muscle invasive bladder cancer and metastatic non small cell lung cancer.
See our latest analysis for ImmunityBio.
ImmunityBio’s share price closed at US$7.64, with a 1-day share price return of 4.37% and a 7-day share price return of 6.56%. The 30-day and 90-day share price returns are both down, hinting at some cooling after a very...